New perspectives in the treatment of schizophrenia

Pakistan Journal of Medical Sciences

Volumn 18, Issue 2, 2002, Pages 135-144

  Kumar Jainer, Ashok ^a   Javed, Afzal ^a   Smith, Ashley ^a   Srivastava, Shrikant ^a  

^a Medical Centre   (United Kingdom)

Author keywords

5 HT receptors; Antipsychotic drugs; D2 receptors; Extrapyramidal symptoms; Schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

AKATHISIA; CLINICAL PRACTICE; CLINICAL TRIAL; DOPAMINE RECEPTOR BLOCKING; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; RIGIDITY; RISK ASSESSMENT; SCHIZOPHRENIA; TREMOR;

EID: 0036310040     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. One-month prevalence of mental disorders in the US: Based on five epidemiological catchment area (ECA) sites
2. Schizophrenia, a high risk factor for suicide: Clues to risk reduction
3. Treatment of schizophrenia
4. The costs of schizophrenia: Assessing the burden
5. Clozapine for treatment resistant schizophrenia: A double-blind comparison with chlorpromazine
6. Dopamine receptor binding predicts clinical and pharmacologic potencies and antischizophrenic drugs
7. Antipsychotic drug doses and neuroleptic/dopamine receptors
8. Dopamine in schizophrenia: A review and reconceptualization
9. The current status of the dopamine hypothesis of schizophrenia
10. CSF and plasma monoamine metabolites and their relation to psychosis: Implications for regional brain dysfunction in schizophrenia
11. The importance of serotonin-dopamine interactions in the action of clozapine
12. Thymostemic effects of ritanserin (R55667), a centrally acting scrotonin S2 blocker
13. Serotonin-dopamine interaction and its relevance to schizophrenia
14. Classification of atypical and typical antipsychotic drugs on the basis of D-1, D-2 and serotonin 2pK1 values
15. Binding of typical and atypical antipsychotic agents to 5HT6 and 5HT7 receptors
16. Genetics of novel therapeutic targets in schizophrenia
17. Positron emission tomography with (18 F) methylspiperone demonstrate D2 dopamine receptor binding differences of clozapine and haloperidol
18. Positive and negative symptoms recovery during clozapine treatment in schizophrenia
19. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia
20. Reduction during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
21. The effects of clozapine on tardive dyskinesia
22. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
23. Depressive sign and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
24. A multicenter, double-blind, placebo-controlled, evaluation of Seroquel in hospitalized patients with acute exacerbation of subchronic and chronic schizophrenia
25. Ziprasidone - An atypical antipsychotic
26. Neuropharmacology of zotepine. An antimanic drug: A potent blocker of D2 and 5HT2 receptors
27. Steady-state serum kinetics of zotepine
28. Zotepine vs haloperidol in paranoid schizophrenia: A double blind trial
29. Delusional depression; treatment with zotepine or haloperidol and antidepressants
30. The efficacy of zotepine in treating acute negative symptoms of schizophrenia: The results of a meta-analysis
31. Risperidone in the treatment of schizophrenia
32. The negative component in schizophrenia
33. The new generation of antipsychotic drugs: How atypical are they?
34. Prescribing in schizophrenia. Evaluating the effect of introducing new treatment protocol
35. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
36. A new algorithm for treating schizophrenia
37. Pre-chnical pharmacology of new atypical antipsychotics in late stage development
38. Risperidone